Aptinyx Stock Is Trading Higher After Restarting NYX-458 Study In Dementia Associated Cognitive Impairment
- Aptinyx Inc (NASDAQ: APTX) has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson's disease and dementia with Lewy bodies.
- Aptinyx will release the data from this study in the second half of 2022.
- The screening was halted due to COVID-19 related restrictions.
- The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study conducted in approximately 100 patients.
- The study will evaluate the overall safety and tolerability of NYX-458 30 mg daily oral dosing compared to placebo over 12 weeks.
- NYX-458 is a novel oral NMDA receptor modulator.
- Price Action: APTX shares jump 9.01% higher at $3.51 in the premarket trading on the last check Tuesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Briefs dementiaBiotech News Penny Stocks Health Care FDA General
